Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study / 대한췌담도학회지
Korean Journal of Pancreas and Biliary Tract
;
: 108-115, 2018.
Article
in English
| WPRIM
| ID: wpr-715804
ABSTRACT
BACKGROUND/AIMS:
This study aimed to compare the outcomes of patients who received systemic chemotherapy or chemoradiotherapy as adjuvant therapies following pancreatic adenocarcinoma resection.METHODS:
We reviewed the medical records of 40 patients with locoregional pancreatic adenocarcinoma who underwent tumor resection at Pusan National University Hospital between 2008 and 2012.RESULTS:
Twenty-nine patients were treated with adjuvant therapy comprising either systemic chemotherapy or chemoradiotherapy after curative-intent surgery. Adjuvant therapy (p=0.025) and complete resection (p=0.043) were associated with longer overall survival. There was no significant difference between chemotherapy and chemoradiotherapy in terms of extending overall survival; however, patients who received chemotherapy had significantly higher survival rates than those who received no adjuvant therapy at all (p=0.012).CONCLUSIONS:
Adjuvant therapies improve the prognoses of patients with resected pancreatic adenocarcinoma; moreover, chemotherapy produced more favorable outcomes than chemoradiotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pancreatic Neoplasms
/
Prognosis
/
Adenocarcinoma
/
Medical Records
/
Survival Rate
/
Retrospective Studies
/
Chemotherapy, Adjuvant
/
Drug Therapy
/
Chemoradiotherapy
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Korean Journal of Pancreas and Biliary Tract
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS